Erratum: International Reports of Unexpected Low Plasma Concentrations of Dabigatran Suggest That More Frequent Measurements Will Add Value

It has been brought to the publisher's attention that the reference citations in [Table 1] were incorrect in the above article in Seminars in Thrombosis and Hemostasis, Volume 43, Number 6, 2017 (DOI: 10.1055/s-0037-1603361).

The references cited in the table are provided below. The correct table appears on the next page.

5 Breuer L, Ringwald J, Schwab S, Köhrmann M. Ischemic stroke in an obese patient receiving dabigatran [letter]. N Engl JMed 2013;368(25):2440–2442

6 Douros A, Schlemm L, Bolbrinker J, Ebinger M, Kreutz R. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome [letter]. Thromb Haemost 2014;112(02):419–420

7 Sargento-Freitas J, Silva F, Pego J, Duque C, Cordeiro G, Cunha L. Cardioembolic stroke in a patient taking dabigatran etexilate: the first case report of clinical and pharmacologic resistance [letter]. J Neurol Sci 2014;346(1–2):348–349

8 Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y bypass surgery [letter]. J Cardiol Cases 2013;8:e49–e50

Table 1 Published reports for dabigatran and below expected within therapy (or unexpectedly low) plasma concentrations

Patient number	Sex/Age	Dose (mg)	Duration of dabigatran use	Time to concentration measurement	Indication	Concomitant drugs	Thrombotic, ischemic or embolic events	Dabigatran concentration method	Dabigatran concentration	aPTT	Comments and other potential contributors
1. Breuer et al, 20135	M/48	150 mg bd	∼31 d	28 and 31 d	AF paroxysmal	Omeprazole	Cerebral infarction, embolic	Hemoclot	Trough not detectable day of stroke, 10 h post dose After witnessed intake for 3 d, peak 50 ng/mL at 4 h	Not reported	Weight 153 kg. BMI 44.7, creatinine clearance 163 mL/min.
2. Douros et al, 20146	F/81	110 mg bd	Not stated	3 mo	AF	Pantoprazole Lercanidipine Clonidine Metoprolol Triamterene Hydrochlorothiazide Furosemide Isosorbide mononitrate	Dysarthria, facial palsy with AF, presumed diagnosis of cardioembolic stroke of cerebral artery	Hemoclot	Peak and trough concentrations, 2 and 12 h after witnessed administration, 31 and 21 ng/mL	Normal at dabigatran trough	Short-gut syndrome following surgery for embolic mesenteric ischemia SNPs affecting liver carboxylesterase and P-glycoprotein GFR (37–43 mL/min).
3. Sargento-Freitas et al, 20147	F/70	110 mg bd	31 d	31 d	AF, acute ischemic stroke, occlusion terminal segment right internal carotid artery	Lorazepam Mirtazapine Furosemide Fluoxetine Simvastatin Bisoprolol Ramipril Digoxin Omeprazole	None	Hemoclot	Peak concentrations after confirmed intake (ng/mL): 1) 40.6 at 31 d, 110 mg bd 2) 41.9 at 5 d, 150 mg bd 3) 45.0 at 7 d, 150 mg bd, interacting medicines stopped.	Normal 7 h after dose in hospital, and at each point when dabigatran concentrations measured.	Creatinine clearance 65 mL/min
4. Lee et al, 20138	F/67	Dose not stated	9 mo	9 mo	AF	Pantoprazole	None	Not stated	Trough concentration 21 ng/mL	Not measured	Roux-en-Y gastric bypass.

Abbreviations: aPTT, activated partial thromboplastin time; AF, atrial fibrillation; bd, twice a day; BMI, body mass index; GFR, glomerular filtration rate; SNP, single nucleotide polymorphism.

No conflict of interest has been declared by the author(s).